Clinical trials
Intensity-modulated Radiotherapy clinical trials
Below are recruiting intensity-modulated radiotherapy clinical trials, each written for real people, not researchers. We’re tracking 57 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05965531RecruitingPhase 2
TAS-102 plus radiation before surgery for rectal cancer
This trial studies whether adding TAS-102 (a chemotherapy medicine) to radiation given before treatment improves outcomes for certain locally advanced rectal cancers. It may help by trying to shrink the tumor before the next steps of care.
Guangzhou, GuangdongAges 18–70 - NCT06749899RecruitingPhase 3
Immunotherapy with chemoradiation for advanced nasopharyngeal cancer
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
Fuzhou, FujianAges 18–65 - NCT07000643RecruitingPhase 3
Proton vs. standard radiation for nasopharyngeal cancer
This trial compares two types of radiation therapy—proton beam versus standard X-ray (photon)—for treating nasopharyngeal cancer. The goal is to see if proton therapy works as well as standard therapy while possibly causing fewer side effects.
JinanAges 18–75 - NCT06914999RecruitingEarly Phase 1
Comparing a new scan to standard scan during head and neck cancer radiation
This trial is testing whether a newer type of PET/CT scan (F-18 NaF) can better detect blood vessel problems caused by radiation therapy than the standard scan (F-18 FDG) in people with head and neck cancer. If successful, it could lead to better ways to prevent and manage these complications.
Atlanta, GeorgiaAges 18 years+ - NCT06890871Enrolling by invitationPhase 1/Phase 2
Radiation with immunotherapy and anti-angiogenic therapy for advanced HER2-negative breast cancer
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Wuhan, HubeiAges 18–75 - NCT06846450RecruitingPhase 3
Comparing radiation types for nasopharyngeal cancer
This trial compares two types of radiation therapy (IMRT or IMPT plus CIRT) to see which works better for patients with nasopharyngeal cancer that hasn't spread. It's for people who have not had radiation to the head or neck before.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06764680RecruitingPhase 2
Oral drugs and radiation for advanced colorectal cancer after standard therapy
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18 years+ - NCT06368817RecruitingPhase 2
Lower radiation dose for children with CNS germinoma
This trial will see if giving a lower dose of radiation therapy can still effectively treat children and young adults with a type of brain tumor called germinoma. The goal is to reduce side effects while keeping the cancer under control.
Mobile, AlabamaAges 3–29 - NCT06349317RecruitingPhase 2
Radiation, immunotherapy, and targeted therapy before surgery for liver cancer with portal vein tumor thrombus
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
Fuzhou, FujianAges 18–75 - NCT06239727RecruitingPhase 3
Reduced-dose radiotherapy for stage III nasopharyngeal cancer based on response
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
Fuzhou, FujianAges 18–65 - NCT06137274RecruitingPhase 2
Adaptive radiation boost for head and neck cancer
This trial tests a new way of giving radiation therapy, called adaptive radiation boost, for people with head and neck cancer. The goal is to see if this approach can better target the cancer and possibly improve outcomes.
Tampa, FloridaAges 18 years+ - NCT05167994RecruitingPhase 2
Pre-surgery radiation plus an anti-cancer drug for soft tissue sarcoma
This Phase 2 trial tests whether giving radiation before surgery, along with anlotinib and penpulimab, can improve treatment for localized soft tissue sarcoma. It may help shrink or control the tumor before conservative surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
Anchorage, AlaskaAges 18 years+ - NCT06507683Recruiting
Radiation plus ripretinib for advanced GIST
This trial tests whether adding radiation therapy to the drug ripretinib can help people with advanced gastrointestinal stromal tumors (GIST) that can't be removed by surgery and have stopped responding to other treatments. It aims to see if this combination is safe and effective.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06250972RecruitingPhase 3
Radiotherapy for advanced pancreatic cancer with normal CA19-9 after chemo
This trial tests whether giving radiotherapy to the pancreas can help people with advanced pancreatic cancer whose CA19-9 level has dropped to normal after chemotherapy. It's for patients whose cancer is still locally advanced (hasn't spread to distant organs).
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06971211RecruitingPhase 2
Radiation and drug combo for advanced prostate cancer
This trial combines radiation therapy with two drugs (fluzopanib and abiraterone acetate) to treat men with metastatic castration-resistant prostate cancer that hasn't been treated yet. The goal is to see if this triple approach helps slow the cancer's growth.
Shenyang, LiaoningAges 18 years+ - NCT05527470RecruitingPhase 3
Chemo then radiation for newly diagnosed advanced nasopharyngeal cancer
This Phase 3 trial tests giving chemotherapy first, then either radiation alone or chemotherapy together with radiation. It aims to improve treatment control for people with newly diagnosed, advanced nasopharyngeal cancer.
Guilin, GuangxiAges 18–65 - NCT06611150RecruitingPhase 1
Chemo and radiation for advanced nasopharyngeal cancer
This trial tests whether a specific chemotherapy drug (nab-paclitaxel) given along with targeted radiation therapy can help people with stage III or IVa nasopharyngeal cancer. The goal is to improve treatment outcomes while managing side effects.
Guangzhou, GuangdongAges 18–70 - NCT07643012Recruiting
Daily MRI-Guided Radiation for Endometrial Cancer
This trial tests whether using MRI scans daily during pelvic radiation therapy improves treatment precision and outcomes for endometrial cancer patients who need radiation after surgery. The goal is to better target cancer while reducing side effects.
New Brunswick, New JerseyAges 18–90 - NCT07441681RecruitingPhase 3
Comparing radiation plus targeted therapy vs standard chemo for head and neck cancer
This trial compares two treatments for advanced head and neck cancer in patients who cannot take the drug cisplatin. One group gets radiation plus a targeted drug called cetuximab, the other gets radiation plus standard chemotherapy. The goal is to see which approach works better and is safer for people who are not candidates for cisplatin.
Beverly Hills, CaliforniaAges 18 years+ - NCT07328841RecruitingPhase 3
Lower radiation dose study for advanced nasopharyngeal cancer
This trial compares a lower dose of radiation to the standard dose for people with advanced nasopharyngeal cancer that shrank after chemotherapy and immunotherapy. The goal is to see if a lower dose works just as well with fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT07333274RecruitingPhase 3
Radiation plus nimotuzumab for head and neck cancer
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
Shandong, ProvinceAges 18 years+ - NCT07293247RecruitingPhase 2
Targeted radiation after lung cancer surgery
This trial tests if targeted radiation after surgery can help people with non-small cell lung cancer who still have cancer in their lymph nodes after chemotherapy. Participants will have had surgery and chemotherapy before starting radiation.
Jonesboro, ArkansasAges 18 years+ - NCT06036706Recruiting
Radiation types and thinking skills for skull base meningioma
This study compares different radiation methods for treating a slow-growing, non-cancerous brain tumor at the base of the skull. It aims to see which approach best protects memory and thinking abilities.
CaenAges 20–65
Hear when a new Intensity-modulated Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for intensity-modulated radiotherapy?
- Yes. Clin2 currently lists 57 recruiting intensity-modulated radiotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a intensity-modulated radiotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a intensity-modulated radiotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.